Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tqb3912
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
TQB3912 is an oral small molecule antineoplastic agent under development by Chia Tai Tianqing Pharmaceutical Group. It functions as a protein kinase inhibitor and is being investigated primarily for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer, particularly in advanced or metastatic settings. The drug is currently in phase I/II clinical trials, often studied in combination with fulvestrant and/or TQB3616 capsules. Its mechanism involves inhibition of phosphorylated protein kinases relevant to tumor growth and progression[1][3][4]. Additional studies are evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced malignant tumors[1][2][4].
- Other names
- TQB 3912TQB3912TQB-3912
02
Targets
PK (Pyruvate kinase)
Beyond the preview
Go deeper on tqb3912.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tqb3912.